Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H40N2O3 |
Molecular Weight | 404.586 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCN(C)CCC[C@](C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1
InChI
InChIKey=SKDZEFVVFACNLS-DEOSSOPVSA-N
InChI=1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1
Molecular Formula | C24H40N2O3 |
Molecular Weight | 404.586 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Nexopamil [LU 49938] is the (S)-enantiomer of a phenylalkylamine derivative and has calcium channel blocking and serotonin2 receptor antagonist activity. Nexopamil's significant antifibrillatory effect during both coronary artery occlusion and abrupt reperfusion is reliably tracked by T-wave alternans magnitude. Because the major component of the protection could be reproduced by blockade of the L-type calcium channel with diltiazem, nexopamil's antiarrhythmic action appears to be due mainly to blockade of this channel. Nexopamil's antiplatelet action through blockade of 5-HT2 receptors may confer additional protection against reperfusion arrhythmias. Nexopamil was discontinued in phase 2 for angina pectoris in European Union.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The effect of LU-49938 (nexopamil) on the activation by serotonin of mesangial cells. | 1995 |
|
Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: comparison to diltiazem. | 1996 Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7523784
Thirty minutes before occlusion, pigs received nexopamil (0.1 mg/kg intravenously, i.v.)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7528308
Nexopamil [LU 49938] inhibited contractions evoked by serotonin, norepinephrine (NE), and prostaglandin F2 alpha (PGF2 alpha) in a concentration-dependent and noncompetitive manner. The lower concentrations of LU 49938 (10(-7) and 10(-6) M) did not affect contractions to serotonin in the presence of ketanserin. However, a higher concentration of LU 49938 (10(-5) M) significantly decreased the concentration-response curve to the monoamine in the presence of ketanserin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:43 GMT 2023
by
admin
on
Fri Dec 15 16:18:43 GMT 2023
|
Record UNII |
ECA0E1PO91
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
||
|
NCI_THESAURUS |
C66885
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000084182
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
SUB09216MIG
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
C66239
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106832
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
65984
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
ECA0E1PO91
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
6935
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY | |||
|
136033-49-3
Created by
admin on Fri Dec 15 16:18:43 GMT 2023 , Edited by admin on Fri Dec 15 16:18:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |